ÂÜÀòÂÒÂ×

Annalisa Adani has a significant amount of work experience in the pharmaceutical industry. Annalisa is currently the VP & Head of Cluster - General Manager Italy, Greece, Cyprus & Malta at Sobi - Swedish Orphan Biovitrum AB (publ). Prior to this, they served as the General Manager Italy & GMT member at Miltenyi Biotec from 2019 to 2022. Annalisa also worked at IQVIA as the Director & Hospital Head, and at Ipsen as the Head of Business Unit & Director - EMEA.

Annalisa Adani has extensive experience at The Medicines Company, where they held the position of Senior Director and Managing Director Italy. During their time there, they were responsible for various aspects including commercial operations, budgeting, forecasting, market access, business development, governance & compliance, and human resources management.

Before joining The Medicines Company, Annalisa Adani worked at AstraZeneca as a Regional Sales & Marketing Manager and District Area Manager/Product Manager. Annalisa started their career as a Sales Rep specialist at SCHERING PLOUGH pharmaceuticals.

Overall, Annalisa Adani has a wealth of experience in leadership, business development, sales, marketing, market access, and operations within the pharmaceutical industry.

Annalisa Adani's education history includes an Executive Summer School in Finance & Strategy at The London School of Economics and Political Science (LSE) in 2014, a Master's degree in CRISPR, Gene editing therapies from Harvard Business School Online from 2018 to 2019, an Executive Summer School in Leadership & Strategy from Harvard Business School in 2013, a Master's degree in Company Internationalization - Focus on Africa Subsaharian & Middle East from SDA Bocconi from 2015 to 2016, and a Laurea in Pharmaceutical Chemist from Alma Mater Studiorum – Università di Bologna from 1987 to 1995. Additionally, they completed a Maturita' scientifica from Liceo in 1987. Currently, they are pursuing a Master in Executive Woman in Leadership from Cornell University.